Fig. 3.
Fig. 3. EBV-specific CD8 T cells are present in the peripheral blood of allo-PBSCT recipients. / PBMCs were obtained from 2 allo-PBSCT recipients at 155 days (patient A) and 212 days (patient B) following transplantation. (A) Patient A was triple-stained with anti-CD8+, CD62L, and HLA tetramers. (B) Patient B was stained with tetramer and anti-CD8 with either anti-CD44, CD45RA, or CD62L. Finally, patient B was stained with an unrelated tetramer/peptide complex as a negative control. The HLA haplotype and the HLA tetramer/peptide complex used for staining are indicated above each plot. Each dot-plot is gated on live CD8+ T cells, and the percentage of CD8 T cells that stain with the respective tetramer is indicated in the upper quadrants of each plot.

EBV-specific CD8 T cells are present in the peripheral blood of allo-PBSCT recipients.

PBMCs were obtained from 2 allo-PBSCT recipients at 155 days (patient A) and 212 days (patient B) following transplantation. (A) Patient A was triple-stained with anti-CD8+, CD62L, and HLA tetramers. (B) Patient B was stained with tetramer and anti-CD8 with either anti-CD44, CD45RA, or CD62L. Finally, patient B was stained with an unrelated tetramer/peptide complex as a negative control. The HLA haplotype and the HLA tetramer/peptide complex used for staining are indicated above each plot. Each dot-plot is gated on live CD8+ T cells, and the percentage of CD8 T cells that stain with the respective tetramer is indicated in the upper quadrants of each plot.

Close Modal

or Create an Account

Close Modal
Close Modal